SJP-001 | Metabolic Recovery | Healthspan & Longevity
Sen-Jam Pharmaceutical is proud to celebrate the recent publication of an insightful new paper by Dr. Joris C. Verster, one of our esteemed scientific advisors and a world-renowned expert in alcohol hangover research. The paper, titled “Alcohol Hangover: Time for a Paradigm Shift,” was just released in the Global Journal of Addiction & Rehabilitation Medicine, and it calls for a fundamental rethinking of how society—and science—addresses the impact of hangovers on public health.
In this powerful editorial, Dr. Verster argues that the traditional perception of hangovers as merely a nuisance overlooks their real-world consequences: impaired cognitive performance, reduced workplace productivity, and increased risk of accidents. He emphasizes the biological underpinnings of hangovers, particularly the inflammatory response triggered by alcohol consumption—an area where Sen-Jam’s own research and drug development efforts are deeply focused. Dr. Verster’s call to action for science, regulators, and the public to take hangovers more seriously resonates strongly with our mission to transform how we treat everyday inflammation-driven conditions.
Dr. Verster brings tremendous depth and credibility to this conversation. He is the founder of the Alcohol Hangover Research Group (AHRG) and a leading academic at Utrecht University and Leiden University in the Netherlands, with over 200 peer-reviewed publications. His commitment to rigorous, evidence-based research continues to advance global understanding of how lifestyle choices intersect with inflammation and health—making him an invaluable member of the Sen-Jam advisory team.
🧠 Read the full paper here: Alcohol Hangover: Time for a Paradigm Shift
📣 As we pioneer the first FDA-approved therapeutic for hangover prevention with SJP-001, we’re proud to have Dr. Verster helping lead the charge.
LINK TO THIS PAPER: https://juniperpublishers.com/gjarm/pdf/GJARM.MS.ID.555721.pdf
Sen-Jam Pharmaceutical Announces Ethics Approval in Australia for SJP-001 Clinical Trial Targeting I...
The End of Sickcare: From the Inside Out: A Spotlight on Cellular Longevity at the Global Passion Pr...
Sen-Jam Pharmaceutical Announces Planned AI Initiative for Molecule Repurposing All Posts The Sen-Ja...